Enhanced APC Therapy for HLA-Agnostic HPV Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HPV-associated cancers are limited, with vaccines being preventive and having side effects, and there are no direct treatments for the virus itself, necessitating new therapeutic options.
Innovation Solution
Administering modified antigen presenting cells (APCs) capable of activating T cells in an HLA-agnostic manner, combined with an immune checkpoint inhibitor, to treat HPV-associated cancers, where the APCs are enhanced with HPV antigens and express co-stimulatory molecules and cytokines, and are prepared through cell deformation and adjuvant conditioning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional HLA-restricted T cell activation methods are used, then T cell activation can be achieved, but the therapeutic response is limited by HLA haplotype diversity
Solution Approach 1:
The patent segments the T cell activation process into two independent components: (1) antigen recognition through modified APCs that present HPV antigens, and (2) HLA-independent co-stimulatory signaling through engineered molecules like CD40L and cytokines. This segmentation allows each component to optimize its function independently, achieving both broad adaptability and reliable activation.
Solution Approach 2:
The patent introduces modified APCs as intermediary cells that bridge the gap between HPV antigens and T cells. These APCs are engineered to express multiple co-stimulatory molecules and cytokines that act as mediators, enabling HLA-agnostic T cell activation while maintaining antigen-specificity through the presentation of HPV antigens.
2Reliability
If HPV infection is left untreated, then no direct therapeutic intervention is needed, but cancer development and progression occur
Solution Approach 1:
The patent employs preliminary action by using modified APCs to prime and activate antigen-specific T cells before they encounter HPV-infected cells in the tumor microenvironment. The APCs are pre-loaded with HPV antigens and engineered to express co-stimulatory molecules, creating a primed immune response that acts preemptively against cancer development.
Solution Approach 2:
The patent converts the harmful HPV antigens (E6, E7 proteins) that drive cancer development into beneficial targets for immune recognition. By loading modified APCs with these same viral antigens, the therapy harnesses the cancer-causing elements as the basis for generating a protective immune response.
3Adaptability or versatility
If existing cancer treatments are used, then some therapeutic effect can be achieved, but treatment options are limited and side effects occur
Solution Approach 1:
The patent creates a universal therapy platform where modified APCs can be applied across multiple HPV-associated cancer types (cervical, oropharyngeal, anal cancers) by simply changing the loaded viral antigens. The same core technology platform addresses diverse clinical scenarios, providing versatility without requiring cancer-type-specific approaches.
Data Source
AI summary
The present application provides enhanced APCs for treating HPV-associated cancers. The enhanced APCs are capable of activating T cells in an HLA agnostic manner and are derived from input APCs in which at least one nucleic acid encoding an HPV antigen has been delivered intracellularly. In some aspects, the enhanced APCs are administered in combination with an immune checkpoint inhibitor, such as an antagonist of PD-1/PD-L1 and/or an antagonist of CTLA-4.